CureVac and EU in advanced talks for 225 million doses of Covid-19 vaccine

Shares of CureVac NV rose Thursday after the German biotech company said it was in advanced talks to deliver at least 225 million doses of a potential Covid-19 vaccine to EU member states.

CureVac said talks with the EC, the executive arm of the European Union, include an option to deliver an additional 180 million doses once the mRNA-based vaccine has been proven to be safe and effective against Covid-19, bringing the total up up to 405 million doses.

The EC is also in talks with Johnson & Johnson JNJ,
+ 0.68%
and France of Sanofi SNY,
for their faxes under development. It also reached an agreement with AstraZeneca AZN last week,
buy at least 300 million doses of its potential Covid-19 vaccine that it is developing with Oxford University.

To read:UK beats two Covid-19 vaccine cases for 90 million doses

CureVac CVAC,
+ 15.99%
specializes in messenger RNA technology, which is the basis of many of Covid-19’s leading faxing programs, including Moderna Inc. MRNA,
and BioNTech SE BNTX,
+ 1.02%.

“In the current pandemic, we are very pleased to reinforce the European Commission’s efforts to provide rapid access to a safe and effective vaccine against the Covid-19 virus throughout Europe and beyond,” said Franz- Werner Haas, CEO of CureVac.

“Adopting positive results from our ongoing clinical trials and regulatory approval, we are fully committed to ensuring broad access to our vaccine,” he added.

Supported by Microsoft founder and billionaire Bill Gates, CureVac reported on the Nasdaq stock market on August 14, raising $ 213 million.

CureVac’s shot up as much as 15% after the opening clock, before mating profit would rise to 8.6% in the morning trading.

To read:CureVac spending rose 249% on its first day of trading. Here’s what it does for an Encore.

CureVac has said that its Covid-19 vaccine could be ready for the public by 2021.

In July, GlaxoSmithKline became PLC GSK,
said it took a stake in CureVac, the latest move by a major drugmaker to increase opportunities to combat pandemics. FTSE 100-listed Glaxo said CureVac’s mRNA technology would complement its own capabilities, as it inked a deal worth up to £ 866 million ($ 1.09 billion).